Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795994 | 0.86 | EPHX2 (0.60) | EPHX2SCN5ASCN9AKCNH2L3MBTL1 | |
| SCHEMBL27913810 | 0.83 | EPHX2 (0.57) | EPHX2SCN5ASCN9AKCNH2L3MBTL1 | |
| SCHEMBL2713919 | 0.83 | EPHX2 (0.60) | EPHX2SCN5ASCN9AKCNH2L3MBTL1 | |
| SCHEMBL796475 | 0.81 | L3MBTL1 (0.72) | EPHX2SCN5ASCN9AKCNH2L3MBTL1 | |
| SCHEMBL25933498 | 0.80 | EPHX2 (0.53) | EPHX2SCN5ASCN9AKCNH2L3MBTL1 | |
| SCHEMBL7799696 | 0.79 | L3MBTL1 (0.50) | EPHX2L3MBTL1MAPT | |
| SCHEMBL1091973 | 0.79 | MAPT (0.55) | L3MBTL1MAPT | |
| SCHEMBL21770762 | 0.78 | SCN1A (0.56) | KCNH2L3MBTL1MAPT | |
| SCHEMBL10972399 | 0.78 | NNMT (0.60) | MAPT | |
| SCHEMBL16422737 | 0.77 | MAPT (0.48) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | EPHX2 1549/4885SCN5A 46/4885SCN9A 1051/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | EPHX2 1549/4885SCN5A 46/4885SCN9A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.